Search - tctmd.com

Displaying 21 - 40 of 299

Sort: Relevancy | Date

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

News Conference News TCT 2024

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

Michael O'Riordan

October 30, 2024

ALIGN-AR at 2 Years Shows Promise for TAVI With Trilogy in Aortic Regurgitation

News Conference News TCT 2024

ALIGN-AR at 2 Years Shows Promise for TAVI With Trilogy in Aortic Regurgitation

Yael L. Maxwell

October 29, 2024

EXPANDed: Atrial Secondary MR Patients Get Clinical Benefit From TEER

News Conference News HFSA 2024

EXPANDed: Atrial Secondary MR Patients Get Clinical Benefit From TEER

October 03, 2024

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

News Conference News HFSA 2024

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

Michael O'Riordan

October 03, 2024

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

News Conference News ESC 2024

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

Michael O'Riordan

September 02, 2024

MitraClip vs Surgery for Severe FMR? MATTERHORN Claims Noninferiority

News Conference News ESC 2024

MitraClip vs Surgery for Severe FMR? MATTERHORN Claims Noninferiority

September 01, 2024

RESHAPE-HF2 Is a Win for MitraClip in FMR—Not Everyone’s On Board

News Conference News ESC 2024

RESHAPE-HF2 Is a Win for MitraClip in FMR—Not Everyone’s On Board

August 31, 2024

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

News Conference News ESC 2024

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

August 31, 2024

AI Assessment of Plaque, Hemodynamics May ID Lesion-Specific ACS Risk

News Conference News SCCT 2024

AI Assessment of Plaque, Hemodynamics May ID Lesion-Specific ACS Risk

July 25, 2024

Treatment Gaps Abound in Heart Failure but Can Be Closed, Studies Show

News Conference News ESC Heart Failure 2024

Treatment Gaps Abound in Heart Failure but Can Be Closed, Studies Show

Michael O'Riordan

May 21, 2024

FFR-Derived Metric Can Identify Focal CAD Best Suited to PCI

News Conference News EuroPCR 2024

FFR-Derived Metric Can Identify Focal CAD Best Suited to PCI

May 20, 2024

INTERACT4: Impact of Prehospital BP-Lowering May Depend on Acute Stroke Type

News Conference News ESOC 2024

INTERACT4: Impact of Prehospital BP-Lowering May Depend on Acute Stroke Type

May 20, 2024

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

News Conference News SCAI 2024

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

May 10, 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

News Conference News ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

April 08, 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

How to Reconcile BEST-CLI and BASIL-2? A ‘Patient-First’ Strategy

News Conference News ISET 2024

How to Reconcile BEST-CLI and BASIL-2? A ‘Patient-First’ Strategy

January 24, 2024

For the Ideal Tricuspid TEER Patient—Look Beyond TRILUMINATE

News Conference News PCR London Valves 2023

For the Ideal Tricuspid TEER Patient—Look Beyond TRILUMINATE

November 20, 2023

Seeing Sticker Price for HFrEF Meds Opens Door to Discussions

News Conference News AHA 2023

Seeing Sticker Price for HFrEF Meds Opens Door to Discussions

November 14, 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

November 11, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.